APHINITY: Adjuvant Pertuzumab + Trastuzumab and Chemotherapy in HER2+ EBC

June 2-6, 2017; Chicago, Illinois
Pertuzumab addition significantly reduced risk of recurrence vs current standard.
Format: Microsoft PowerPoint (.ppt)
File Size: 501 KB
Released: June 5, 2017

Acknowledgements

Supported by educational grants by
AbbVie
Amgen
AstraZeneca
Celgene Corporation
Genentech
Halozyme Therapeutics
Incyte
Merck & Co., Inc.

Related Content

Expert faculty provide insights into the role and utility of Ki-67 testing in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

person default Sunil Badve, MD, FRCPath Laura M. Spring, MD Released: September 26, 2022

Dr Denise Yardley discusses key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 22, 2022 Expired: September 21, 2023

Downloadable slides from Dr Denise Yardley on key ongoing trials in HR-positive/HER2-negative early breast cancer, from Clinical Care Options (CCO)

Denise A. Yardley, MD Released: September 22, 2022

Slideset from Dr Denise Yardley on immunotherapy in early TNBC, from Clinical Care Options (CCO)

Denise A. Yardley, MD
Program Director
Released: September 15, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings